$SBBP News Article - Strongbridge Biopharma plc Announces U.S. Food & Drug Administration (FDA) Filing Acceptance of New Drug Application (NDA) for RECORLEV (levoketoconazole) for the Treatment of Endogenous Cushing's Syndrome
https://marketwirenews.com/news-releases/stro...47613.html